-
摘要: 目前听神经瘤的治疗方式以手术治疗为主，考虑到手术带来的多种并发症风险和患者的主/客观条件，非手术治疗中的立体定位放射治疗逐渐成为听神经瘤治疗的一部分。研究表明，伽马刀治疗对较小的肿瘤治疗效果较突出，并可缓解因肿瘤占位带来的面神经及听神经疾病。赛博刀不仅对肿瘤的控制效果较好，而且患者的听功能保留率也较为理想。质子束疗法也逐渐应用于听神经瘤的治疗，但还需进一步研究。药物治疗(包括多种靶点抑制剂与抗血管生成药物)目前多聚焦于临床前研究。本文对多种放射治疗临床研究与药物治疗进展进行综述。Abstract: At present, the main treatment for vestibular schwannomas is surgery. Considering the risk of multiple complications from surgery and the subjective and objective conditions of patients, a non-surgical treatment modality, namely stereotactic radiotherapy, has gradually been included in the treatment of vestibular schwannomas. Studies have shown that Gamma Knife therapy has a more prominent therapeutic effect on smaller tumors and can alleviate facial nerve disorders caused by space occupying of tumor mass. Cyberknife not only has a better effect on tumor control, but also has an ideal retention rate for patients' auditory function. Proton beam therapy has also been gradually applied to the treatment of vestibular schwannomas, but the effect of treatment remains to be further studied. Drug therapy includes a variety of target inhibitors and anti-angiogenic drugs. At present, drug treatment focuses more on preclinical research. This article reviews the clinical research of various radiotherapy and the progress of drug treatment.
-
Key words:
- vestibular schwannomas /
- radiation therapy /
- drug therapy /
- auditory function
-
-
[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010—2014[J]. Neuro Oncol, 2017, 19(suppl_5): v1-v88.
[2] Evans DG. Neurofibromatosis type 2[J]. Handb Clin Neurol, 2015, 132: 87-96.
[3] Halliday J, Rutherford SA, McCabe MG, et al. An update on the diagnosis and treatment of vestibular schwannoma[J]. Expert Rev Neurother, 2018, 18(1): 29-39. doi: 10.1080/14737175.2018.1399795
[4] 朱雅静, 单春光. Merlin蛋白及其信号通路在肿瘤中的研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(9): 757-762. doi: 10.13201/j.issn.1001-1781.2016.09.023
[5] Sethi M, Borsetto D, Bance M, et al. Determinants of Vestibular Schwannoma Growth[J]. Otol Neurotol, 2021, 42(5): 746-754.
[6] Reznitsky M, Petersen M, West N, et al. The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort[J]. Neuro Oncol, 2021, 23(5): 827-836. doi: 10.1093/neuonc/noaa230
[7] 吴皓. 中国耳鼻咽喉头颈外科罕见病诊治现状[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(9): 793-798. doi: 10.13201/j.issn.1001-1781.2019.09.001
[8] Leksell L. A note on the treatment of acoustic tumours[J]. Acta Chir Scand, 1971, 137(8): 763-765.
[9] Dutta D, Balaji Subramanian S, Murli V, et al. Dosimetric comparison of Linac-based(BrainLAB®)and robotic radiosurgery(CyberKnife ®)stereotactic system plans for acoustic schwannoma[J]. J Neurooncol, 2012, 106(3): 637-642. doi: 10.1007/s11060-011-0703-5
[10] Wu CC, Guo WY, Chung WY, et al. Magnetic resonance imaging characteristics and the prediction of outcome of vestibular schwannomas following Gamma Knife radiosurgery[J]. J Neurosurg, 2017, 127(6): 1384-1391. doi: 10.3171/2016.9.JNS161510
[11] Benghiat H, Heyes G, Nightingale P, et al. Linear accelerator stereotactic radiosurgery for vestibular schwannomas: a UK series[J]. Clin Oncol(R Coll Radiol), 2014, 26(6): 309-315. doi: 10.1016/j.clon.2014.02.008
[12] Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4): 985-997. doi: 10.1016/j.ijrobp.2010.10.010
[13] Milligan BD, Pollock BE, Foote RL, et al. Long-term tumor control and cranial nerve outcomes following γ knife surgery for larger-volume vestibular schwannomas[J]. J Neurosurg, 2012, 116(3): 598-604. doi: 10.3171/2011.11.JNS11811
[14] Huang MJ, Kano H, Mousavi SH, et al. Stereotactic radiosurgery for recurrent vestibular schwannoma after previous resection[J]. J Neurosurg, 2017, 126(5): 1506-1513. doi: 10.3171/2016.5.JNS1645
[15] Sun S, Liu A. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2[J]. J Neurosurg, 2014, 121 Suppl: 143-149.
[16] Adler JR Jr, Chang SD, Murphy MJ, et al. The Cyberknife: a frameless robotic system for radiosurgery[J]. Stereotact Funct Neurosurg, 1997, 69(1-4 Pt 2): 124-128.
[17] Dewas S, Dewas-Vautravers C, Servent V, et al. Results and special considerations when treating elderly patients with CyberKnife®: a review of 345 cases[J]. Crit Rev Oncol Hematol, 2011, 79(3): 308-314. doi: 10.1016/j.critrevonc.2010.09.006
[18] Mahboubi H, Maducdoc MM, Yau AY, et al. Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations[J]. Otolaryngol Head Neck Surg, 2015, 153(5): 822-831. doi: 10.1177/0194599815573223
[19] Vivas EX, Wegner R, Conley G, et al. Treatment outcomes in patients treated with CyberKnife radiosurgery for vestibular schwannoma[J]. Otol Neurotol, 2014, 35(1): 162-170. doi: 10.1097/MAO.0b013e3182a435f5
[20] Çakır O, Berkiten G, Tutar B, et al. Effects of CyberKnife therapy for vestibular schwannoma on hearing: a retrospective study[J]. J Laryngol Otol, 2018, 132(9): 796-801. doi: 10.1017/S0022215118001500
[21] Wu CH, Chen CM, Cheng PW, et al. Acute sensorineural hearing loss in patients with vestibular schwannoma early after cyberknife radiosurgery[J]. J Neurol Sci, 2019, 399: 30-35. doi: 10.1016/j.jns.2019.02.008
[22] Koetsier KS, Hensen EF, Niemierko A, et al. Outcome and Toxicity of Proton Therapy for Vestibular Schwannoma: A Cohort Study[J]. Otol Neurotol, 2021, 42(10): 1560-1571. doi: 10.1097/MAO.0000000000003313
[23] Saraf A, Pike LRG, Franck KH, et al. Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial[J]. Neurosurgery, 2022, 90(5): 506-514. doi: 10.1227/neu.0000000000001869
[24] Tawfik KO, Alexander TH, Saliba J, et al. The Effect of Tumor Size on Likelihood of Hearing Preservation After Retrosigmoid Vestibular Schwannoma Resection[J]. Otol Neurotol, 2020, 41(10): e1333-e1339. doi: 10.1097/MAO.0000000000002882
[25] Dowling EM, Patel NS, Lohse CM, et al. Durability of Hearing Preservation Following Microsurgical Resection of Vestibular Schwannoma[J]. Otol Neurotol, 2019, 40(10): 1363-1372. doi: 10.1097/MAO.0000000000002378
[26] Akpinar B, Mousavi SH, McDowell MM, et al. Early Radiosurgery Improves Hearing Preservation in Vestibular Schwannoma Patients With Normal Hearing at the Time of Diagnosis[J]. Int J Radiat Oncol Biol Phys, 2016, 95(2): 729-734. doi: 10.1016/j.ijrobp.2016.01.019
[27] A R P, Yeole U, Arimappamagan A, et al. Effect of Gamma Knife Radiosurgery on Vestibular Schwannoma with Serviceable Hearing: A Single-Center Indian Study[J]. World Neurosurg, 2019, 127: e114-e123. doi: 10.1016/j.wneu.2019.02.169
[28] Han MS, Jung S, Lim SH, et al. What Clinicians Should Consider to Determine a More Beneficial Treatment Strategy for Small to Medium Sized Vestibular Schwannoma With Serviceable Hearing: A Single Surgeon's Long-term Outcome of Microsurgery and Gamma Knife Radiosurgery[J]. Otol Neurotol, 2020, 41(8): 1122-1130. doi: 10.1097/MAO.0000000000002721
[29] Jia H, Sterkers O, Pavillon-Maisonnier C, et al. Management and Outcomes of Sporadic Vestibular Schwannoma: A Longitudinal Study Over 12 Years[J]. Laryngoscope, 2021, 131(3): E970-E976.
[30] Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates[J]. Neurosurgery, 2007, 60(3): 460-8;discussion 468-470.
[31] Hedger G, Sansom MS, Koldsø H. The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids[J]. Sci Rep, 2015, 5: 9198. doi: 10.1038/srep09198
[32] Sabbah M, Najem A, Krayem M, et al. RTK Inhibitors in Melanoma: From Bench to Bedside[J]. Cancers(Basel), 2021, 13(7).
[33] Wang B, Tang Q, Xu L, et al. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors[J]. Mod Pathol, 2021, 34(1): 42-50. doi: 10.1038/s41379-020-0636-7
[34] Mota M, Shevde LA. Merlin regulates signaling events at the nexus of development and cancer[J]. Cell Commun Signal, 2020, 18(1): 63. doi: 10.1186/s12964-020-00544-7
[35] Bush ML, Burns SS, Oblinger J, et al. Treatment of vestibular schwannoma cells with ErbB inhibitors[J]. Otol Neurotol, 2012, 33(2): 244-257. doi: 10.1097/MAO.0b013e31823e287f
[36] Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma[J]. Neuro Oncol, 2010, 12(8): 834-843. doi: 10.1093/neuonc/noq012
[37] Clark JJ, Provenzano M, Diggelmann HR, et al. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study[J]. Otol Neurotol, 2008, 29(6): 846-853. doi: 10.1097/MAO.0b013e31817f7398
[38] Ishii Y, Hamashima T, Yamamoto S, et al. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor[J]. Pathol Int, 2017, 67(5): 235-246. doi: 10.1111/pin.12530
[39] Li T, Guo T, Liu H, et al. Platelet derived growth factor BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes associated protein signaling pathway[J]. Oncol Rep, 2021, 45(1): 83-94.
[40] Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia[J]. Future Oncol, 2019, 15(9): 953-965. doi: 10.2217/fon-2018-0468
[41] Ammoun S, Schmid MC, Triner J, et al. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2[J]. Neuro Oncol, 2011, 13(7): 759-766. doi: 10.1093/neuonc/nor056
[42] Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1): 87. doi: 10.1038/s41392-020-0187-x
[43] Ammoun S, Evans DG, Hilton DA, et al. Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2[J]. J Neurol Neurosurg Psychiatry, 2019, 90(10): 1184-1187. doi: 10.1136/jnnp-2018-319713
[44] Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy[J]. Cold Spring Harb Perspect Med, 2016, 6(10).
[45] 孟文霞, 王宝山. 喉鳞状细胞癌的表观遗传调控研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(22): 1758-1762. doi: 10.13201/j.issn.1001-1781.2018.22.019
[46] Zucchetti B, Shimada AK, Katz A, et al. The role of histone deacetylase inhibitors in metastatic breast cancer[J]. Breast, 2019, 43: 130-134. doi: 10.1016/j.breast.2018.12.001
[47] Spartalis E, Kotrotsios K, Chrysikos D, et al. Histone Deacetylase Inhibitors and Papillary Thyroid Cancer[J]. Curr Pharm Des, 2021, 27(18): 2199-2208. doi: 10.2174/1381612826666201211112234
[48] Bush ML, Oblinger J, Brendel V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas[J]. Neuro Oncol, 2011, 13(9): 983-999. doi: 10.1093/neuonc/nor072
[49] Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer[J]. Annu Rev Pathol, 2009, 4: 127-150. doi: 10.1146/annurev.pathol.4.110807.092311
[50] Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress[J]. Mol Cell, 2010, 40(2): 310-322. doi: 10.1016/j.molcel.2010.09.026
[51] Lee BJ, Boyer JA, Burnett GL, et al. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth[J]. Nat Chem Biol, 2021, 17(10): 1065-1074. doi: 10.1038/s41589-021-00813-7
[52] Laplante M, Sabatini DM. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2): 274-293. doi: 10.1016/j.cell.2012.03.017
[53] Giovannini M, Bonne NX, Vitte J, et al. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma[J]. Neuro Oncol, 2014, 16(4): 493-504. doi: 10.1093/neuonc/not242
[54] Koutsimpelas D, Stripf T, Heinrich UR, et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics[J]. Otol Neurotol, 2007, 28(8): 1094-1099. doi: 10.1097/MAO.0b013e31814b2787
[55] Wong HK, Lahdenranta J, Kamoun WS, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors[J]. Cancer Res, 2010, 70(9): 3483-3493. doi: 10.1158/0008-5472.CAN-09-3107
[56] Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2[J]. N Engl J Med, 2009, 361(4): 358-367. doi: 10.1056/NEJMoa0902579
-
计量
- 文章访问数: 1345
- PDF下载数: 1259
- 施引文献: 0
下载: